Article
Mutations in <i>fbiD (Rv2983)</i> as a novel determinant of resistance to pretomanid and delamanid in <i>Mycobacterium tuberculosis</i>
2020-09-11
Abstract excerpt
<h4>ABSTRACT</h4> The nitroimidazole pro-drugs delamanid and pretomanid comprise one of only two new antimicrobial classes approved to treat tuberculosis (TB) in 50 years. Prior in vitro studies suggest a relatively low barrier to nitroimidazole resistance in Mycobacterium tuberculosis , but clinical evidence is limited to date. We selected pretomanid-resistant M. tuberculosis mutants in two mouse models of TB...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- d8de4d38-cfcb-5c31-b323-3d22774ad7fb
- DOI
- 10.1101/2020.09.10.292508
